AMDA Pocket Guidelines

UTIs in the Post-Acute and Long-Term Care Setting

AMDA GUIDELINES App Bundle brought to you courtesy of AMDA and Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1222827

Contents of this Issue

Navigation

Page 11 of 27

Treatment 12 Table 1. Continued UTI Syndrome and Associated Clinical and Microbiological Findings a Recommended Treatment and Duration b Additional Comments Acute pyelonephritis Diagnostic Test Results: ≥100,000 CFUs/mL of ≤2 species of bacteria OR ≥100 CFUs/mL of ≥1 species of bacteria in a specimen collected by in- and-out catheter Signs & Symptoms: Non-localizing, suggesting that the illness extends beyond the bladder, such as fever, c rigors/chills, marked fatigue/malaise, nausea or vomiting, AND Localizing to the genito-urinary tract, such as dysuria, suprapubic tenderness, costovertebral angle tenderness, pelvic or perineal pain (men), new or worsening incontinence, frequency, urgency, or gross hematuria Trimethoprim/ Sulfamethoxazole, 14 days Beta-lactams, 10–14 days Fluoroquinolones, 7 days Nitrofurantoin and fosfomycin should not be used to treat pyelonephritis. Pyelonephritis may present without symptoms of cystitis. Shorter (7–10 days) treatment with trimethoprim/sulfamethoxazole may be appropriate in select patients with rapid defervescence. Pelvic or perineal pain in men can suggest accompanying prostatitis. a Clinical and microbiological findings in this table have been provided to highlight differences in various UTI syndromes. PALTC settings are recommended to adapt one of the published clinical algorithms to guide the diagnosis and decision to initiate antibiotics for residents with a suspected UTI. b When choosing an antibiotic agent, clinicians will also need to consider additional factors including (but not limited to) resident allergies, co-morbidities, potential drug-drug interactions, availability, local resistance pattern/urine culture results, cost and overall clinical status. Similarly, final treatment duration will also depend on overall clinical condition and response to the treatment. c More recently published criteria usually define fever as: Single oral temperature of ≥100°F or repeated oral temperatures of >99°F or increase in temperature of ≥2°F over baseline. Source: Ashraf MS et al. Diagnosis, Treatment, and Prevention of Urinary Tract Infections in Post- Acute and Long-Term Care Settings: A Consensus Statement From AMDA's Infection Advisory Subcommittee. J Am Med Dir Assoc. 2020 Jan;21(1):12-24

Articles in this issue

view archives of AMDA Pocket Guidelines - UTIs in the Post-Acute and Long-Term Care Setting